October 21, 2025

Yelenis Seijo De Armas, M.D., Joins Baptist Health Heart & Vascular Care as a Cardiologist

Cardiologist Yelenis Seijo De Armas, M.D., has joined Baptist Health Heart & Vascular Care at Baptist Health Miami Cardiac & Vascular Institute

Baptist Health South Florida

October 21, 2025

Industry Insights: Pride in Precision Medicine

Rita Shaknovich, Chief Medical Officer at Agilent Technologies, shares her insights into automation, access, and analytics

The Pathologist

October 21, 2025

Unfolding the Hidden Flexibility of GPCRs

A cross-linking mass spectrometry approach exposes dynamic interactions long hidden from traditional structural biology

The Analytical Scientist

October 21, 2025

Night Driving: "We Have a Lens for That"

UK optical practices encouraged to promote new diagnostics and lenses to address night driving challenges

The Ophthalmologist

October 20, 2025

Alvaro I. Martinez Jr., M.D., FACC, Joins Baptist Health Heart & Vascular Care

Board-certified cardiologist Alvaro I. Martinez Jr., M.D., has joined Baptist Health Heart & Vascular Care at Baptist Health Miami Cardiac & Vascular Institute.

Baptist Health South Florida

October 20, 2025

Using Raman Spectroscopy to Assess Embryo Viability in IVF

Analysis of embryo culture medium reveals protein and pH signatures linked to blastocyst grade and pregnancy outcomes

The Analytical Scientist

October 20, 2025

From the Apollo Era to the World's First Cell Therapy

Bruce Levine shares his journey from a childhood steeped in science to co-founding the first CAR T-cell trials, and explains why communication and regulatory collaboration are crucial for the field’s future.

The Medicine Maker

October 20, 2025

A Two-Photon Window into Diabetic Neurovascular Dynamics

AI-powered eye implant restores functional vision to people who had lost all sight

The Ophthalmologist

October 19, 2025

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.

Dana-Farber